Life sciences

Copyright © 2025 LexisNexis

The life sciences sector encompasses companies in the fields of pharmaceuticals, biotechnology and medical technology that focus on the research, development and commercialisation of a wide range of products that have a medical application. Such products include pharmaceuticals (ie everything from over-the-counter painkillers to advanced therapies for treating diseases such as cancer or HIV), medical devices (eg plasters, syringes, heart stents, pacemakers, etc) and diagnostics.

Understandably, the life sciences sector is highly regulated and the development and commercialisation of products in the life sciences sector is subject to stringent rules. However, there is not one clearly defined body of ‘pharmaceutical’ or ‘life sciences’ law, instead, a complex framework of rules exists that derives from a variety of sources. In the EU, a large amount of the regulation originates from directives or regulations and is supplemented by guidance issued by the European Commission and by the European Medicines Agency (EMA), the decentralised agency of the EU responsible for the scientific evaluation, supervision and safety monitoring of medicines.

Trackers

Practice Notes: Life sciences tracker—EU and Life sciences cases tracker—EU are intended to be used to track the progress of

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Existing user? Sign-in TAKE A FREE TRIAL
Powered by Lexis+®
Latest EU Law News

Commission opens consultation on geographical indications delegated regulation

The European Commission has launched a consultation on a draft delegated regulation that will supplement Regulation (EU) 2023/2411 on geographical indications (GIs) for craft and industrial products. The draft regulation specifies requirements for GI application documentation, submission procedures to the European Union Intellectual Property Office (EUIPO), direct registration criteria, and appeal processes. The consultation period runs from 30 June 2025 to 28 July 2025.

EIOPA launches consultation on revised supervisory review guidelines under Solvency II

The European Insurance and Occupational Pensions Authority (EIOPA) has launched a public consultation on draft revised Guidelines on the Supervisory Review Process. The primary objective of the revision is to clarify existing instructions in light of the Solvency II review and to bring emerging risks within scope. The proposed amendments aim to align the Guidelines with recent regulatory developments and supervisory best practices, while introducing new processes to address risks and trends that have emerged since the Guidelines were first adopted. The draft includes new sections on business model analysis, joint on-site inspections, early intervention measures, pre-emptive recovery planning, and supervision of conduct of business. EIOPA has also introduced guidance to ensure that supervisors incorporate sustainability risks, IT and cyber risks, and Supervisory Technology (SupTech) into their review processes. EIOPA says the amendments are targeted and limited, reflecting its commitment to regulatory simplification and burden reduction. Responses are sought by 24 September 2025.

ESMA publishes list of MiCA grandfathering periods adopted by Member States

The European Securities and Markets Authority (ESMA) has published an updated list detailing the grandfathering periods adopted by Member States under Article 143 of the Markets in Cryptoassets Regulation (Regulation) (EU) 2023/1114) (MiCA). These transitional measures allow cryptoasset service providers (CASPs) that were operating in accordance with applicable national law before 30 December 2024 to continue their activities temporarily—until 1 July 2026 or until they are granted or refused authorisation under Article 63 of MiCA, whichever comes first.

EU CRR: EBA launches consultation on amended Guidelines on application of the definition of default

The European Banking Authority (EBA) has launched a consultation on proposed amendments to its Guidelines on the application of the definition of default of the Capital Requirements Regulation (EU) No 575/2013 (EU CRR). The amendments follow the EBA’s mandate under Article 178(7) of the EU CRR, as revised by Regulation (EU) 2024/1623, and aim to ensure institutions retain sufficient flexibility while maintaining robust risk management standards. Responses are sought by 15 October 2025, with a public hearing scheduled for 3 September 2025 (registration deadline: 29 August 2025).

View EU Law by content type :  
News
Practice notes
Precedents
Q&As

Popular documents

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an
What is the difference between an appeal and a review?

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit

Contributory negligence in personal injury claims

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an